

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Pro Medicus Limited
ABN	25 006 194 752

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sam Aaron HUPERT
Date of last notice	19 February 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Ordinary fully paid shares in Pro Medicus Limited held by Sam Aaron HUPERT
Date of change	15 March 2023
No. of securities held prior to change	27,137,660 ordinary shares consisting of:- <ul style="list-style-type: none">• 27,072,660 ordinary shares held under Sam Aaron HUPERT• 65,000 ordinary shares held under Alltogether Superannuation Fund
Class	Ordinary shares
Number acquired	Nil
Number disposed	1,000,000 ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$62.22 per share
No. of securities held after change	26,137,660 ordinary shares consisting of:- <ul style="list-style-type: none"> • 26,072,660 ordinary shares held under Sam Aaron HUPERT • 65,000 ordinary shares held under Alltogether Superannuation Fund
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For and on behalf of Pro Medicus Limited



Clayton Hatch
Company Secretary
16 March 2023

⁺ See chapter 19 for defined terms.